Search

Abstract Background Integrase inhibitors (INIs)-based antiretroviral therapies (ART) are more recommended than efavirenz (EFV)-based ART for people living with HIV/AIDS (PLWHA). Yet, the advantage of integrase inhibitors in treating TB/HIV coinfection is uncertain. Therefore, the objective of this systematic review is to evaluate the effects and safety of INIs- versus EFV-based ART in TB/HIV coinfection, and demonstrate the feasibility of the regimens. Methods Four electronic databases were systematically searched through September 2020. Fixed-effects models were used to calculate pooled effect size for all outcomes. The primary outcomes were virologic suppression and bacteriology suppression for INIs- versus EFV-based ART. Secondary outcomes included CD4+ cell counts change from baseline, adherence and safety. Results Three trials (including 672 TB/HIV patients) were eligible. ART combining INIs and EFV had similar effects for all outcomes, with none of the point estimates argued against the INIs-based ART on TB/HIV patients. Compared to EFV-based ART as the reference group, the RR was 0.94 (95% CI 0.85 to 1.05) for virologic suppression, 1.00 (95% CI 0.95 to 1.05) for bacteriology suppression, 0.98 (95% CI 0.95 to 1.01) for adherence. The mean difference in CD4+ cell counts increase between the two groups was 14.23 cells/μl (95% CI 0− 6.40 to 34.86). With regard to safety (adverse events, drug-related adverse events, discontinuation for drugs, grade 3–4 adverse events, IRIS (grade 3–4), and death), INIs-based regimen was broadly similar to EFV-based regimens. The analytical results in all sub-analyses of raltegravir- (RAL) and dolutegravir (DTG) -based ART were valid. Conclusion This meta-analysis demonstrates similar efficacy and safety of INIs-based ART compared with EFV-based ART. This finding supports INIs-based ART as a first-line treatment in TB/HIV patients. The conclusions presented here still await further validation owing to insufficient data.

In view of the complex and severe challenges faced by financial technology regulation and the lag behind situation of the existing regulatory sandbox which is highly dependent on manual operation,the important feature and development trend of the Chinese “innovative regulatory tools on financial technology” lie in “intelligence” were pointed out.A systematic platform framework of “intelligent innovative regulatory tools on financial technology” was proposed,that is,use modern means of science and technology to realize the full life cycle supervision of financial technology innovative applications.The elements of innovative regulatory tools were elaborated,including the underlying blockchain,public opinion monitoring platform,explainable artificial intelligence based on knowledge graphs,and presented the key technologies involved.The new iterative methodology used in the development of the innovative regulatory tools platform was introduced,i.e.,the spiral development model and iterative design driven by the hierarchy of needs.Towards the end,some thoughts and prospects on the proposed innovative regulatory tools were put forward,and the regulatory tools are expected to create a set of regulatory technology infrastructure to serve regulatory authorities and financial institutions were pointed out.

Abstract Background Baricitinib, an oral-administrated selective inhibitor of the JAK1 and JAK2, is recently approved for rheumatoid arthritis (RA) treatment. With the aim to provide some insights on the clinical safety, the current study mainly focused on the effect of baricitinib on low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels and cardiovascular risk. Methods The net change scores [least squares mean (LSM) and mean change] of LDL-C and HDL-C levels from baseline with the comparison of baricitinib versus placebo were pooled, respectively. Risk rations (RR) of major cardiovascular events (MACEs) and differences of cardiovascular risk scores at the end of treatment across groups were compared. Results Six trials with randomized 3552 patients were finally included in summary analysis. Results showed that baricitinib significantly increased LDL-C levels, the net mean change was 13.15 mg/dl with 95% CI 8.89~17.42 (I2 = 0) and the net LSM was 11.94 mg/dl with 95% CI 7.52~16.37 (I2 = 84%). HDL-C also increased obviously with the net LSM change was 7.19 mg/dl (95% CI, 6.05~8.33, I2 = 47%) and net mean change was 5.40 mg/dl (95% CI, 3.07~7.74, I2 = 10%). Subgroup and meta-regression analysis demonstrated baricitinib induced LDL-C and HDL-C increases in a dose-response manner. However, both the pooled RRs of MACEs and differences of cardiovascular risk scores were not statistically significant across groups. Conclusion This study confirmed that baricitinib induced a stable dose-response increase in LDL-C and HDL-C levels. Since the causality association between altered lipids and cardiovascular risk was not identified yet, this issue cannot be completely dismissed. Future research is needed to fully dissect the implications of these lipid changes.

This research aimed to investigate the effect of degree of milling on the cooking properties and edible quality of the sea rice. The study examined the cooking quality, sensory attributes, and texture properties of the cooked sea rice with different degree of milling. In this experiment, sea rice with different degree of milling (0%, 7.20%, 9.62%, 10.85% and 11.86%) were prepared by controlling the milling time. The quality attributes of cooked sea rice were analyzed by rapid viscosity analyzer (RVA), texture analyzer and sensory evaluation. As the milling degree increased from 0% to 11.86%, the total dietary fiber content in sea rice decreased by 86.07%, while protein content decreased by 31.84% and fat content decreased by 77.18%. Conversely, the starch content increased by 7.12%. The results of the study indicated significant increases in the water absorption, swelling rate, iodine blue value, and water solubility index (65~85 ℃) of sea rice by 129.66%, 178.45%, 114.63%, and 46.79%~103.89%, respectively (P0.05). Interestingly, the rice sensory evaluation score showed a substantial increase of 19.30%. The results of the study indicate that increasing the degree of milling of sea rice can improve its cooking properties, pasting characteristics, texture, overall sensory properties, and edible quality. Therefore, this study can provide a theoretical basis for choosing the suitable degree of milling of sea rice.

A new strategy of simplification therapy shown the unique benefits in clinical treatment, by reducing pill burden and avoid drug exposure. To provide more evidence for the strategy, we compared the efficacy and safety of dolutegravir (DTG)-containing simplified dual combination antiretroviral therapy (cART) and traditional triple cART for people living with HIV/AIDS. The meta-analysis of randomized controlled trials compared DTG-containing dual therapy with triple cART. The primary outcome was virologic suppression. The secondary outcomes included CD4T cell recovery, lipids change from baseline, and adverse events (AEs). A total of 7 studies, 4852 patients were eligible, 2423 (49.9%) received DTG-based simplified dual cART, and 2429 (50.1%) received triple cART. The viral suppression rate was 94.7% at 24 weeks, 93.0% at 48 weeks, and 96.6% at 96 weeks in dual cART. The viral suppression rate of dual cART was non-inferior to triple cART at 24 weeks (risk difference [RD], -0.00; 95% confidence interval [CI] -0.02-0.01), at 48 weeks (RD, -0.01; 95% CI -0.02-0.01), and at 96 weeks (RD, -0.01; 95% CI -0.02-0.00). Sub-analysis results were consistent with the overall results. With regard to other outcomes (CD4T counts, lipids, any AEs, and AEs grade ≥ 3), there was no significant statistical difference between the two regimens. DTG-based simplified dual cART was non-inferior to triple cART in terms of efficacy and safety. This finding provides strong support for current consensus guidelines recommended the dual regimen as first-line treatment. [ABSTRACT FROM AUTHOR]

Abstract This paper reports the first universal and versatile database on aggregate materials for the field of aggregate science research. At the current stage, the database (http://119.91.135.188:8080/) contains over 1000 entries of organic aggregate material systems (mainly luminescent systems at the current stage) with a unique data structure which is designed particularly for aggregate materials and containing the photophysics and physicochemical properties of the compounds in different statuses of aggregation, including dilute solution form, pristine solid‐state, stable crystalline, and nanoaggregates formed in solvents. The web‐based interface of the database provided functions to index, search, manipulate, fetch and deposit data entries. In addition, a background calculation service optimizes the chemical structure of new entries on different levels of accuracies. The database also provided background API for interactive developments of prediction or regression models based on machine‐learning algorithms.